Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1995 Aug;74(2):140–148. doi: 10.1136/hrt.74.2.140

Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol.

H Persson 1, E Rythe'n-Alder 1, A Melcher 1, L Erhardt 1
PMCID: PMC483989  PMID: 7546992

Abstract

OBJECTIVE--To evaluate whether xamoterol, a partial agonist, would improve exercise time more than metoprolol in patients with mild to moderate heart failure after a myocardial infarction. DESIGN--Single-centre double blind randomised parallel group comparison of metoprolol 50-100 mg and xamoterol 100-200 mg twice daily. PATIENTS--210 patients aged 40-80 years (173 men) with clinical evidence of heart failure early after a myocardial infarction. 106 were given metoprolol and 104 xamoterol. MAIN OUTCOME MEASURES--Exercise test results and performance at three months; the exercise test, quality of life, and clinical assessments at baseline (5-7 days after the infarction) and after 3, 6, and 12 months. RESULTS--Exercise time increased at three months by 22% in the metoprolol group and 29% in the xamoterol group, but with no significant difference between the groups. Patients taking xamoterol showed overall non-significantly higher mean values of exercise time achieved with higher heart rates at rest and exercise. Improvements in quality of life, clinical signs of heart failure, and New York Heart Association functional class were seen in both treatment groups over one year, with minor benefits of xamoterol on breathlessness, peripheral oedema, and functional class. Eighteen patients taking metoprolol and 22 taking xamoterol withdrew from the study during one year, with a low mortality, reinfarction rate, and progress of heart failure in both treatment groups. Mean dose from baseline to 3 months was 135 mg metoprolol and 347 mg xamoterol. CONCLUSION--beta 1 Receptor antagonists with or without partial agonist activity are safe to use in mild to moderate heart failure after a myocardial infarction. Exercise tolerance, quality of life, and clinical signs and functional class of heart failure improve, and few patients show deterioration in their condition. Exercise tolerance is no better with xamoterol than metoprolol.

Full text

PDF
140

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berning J., Rokkedal Nielsen J., Launbjerg J., Fogh J., Mickley H., Andersen P. E. Rapid estimation of left ventricular ejection fraction in acute myocardial infarction by echocardiographic wall motion analysis. Cardiology. 1992;80(3-4):257–266. doi: 10.1159/000175011. [DOI] [PubMed] [Google Scholar]
  2. Berning J., Steensgaard-Hansen F., Appleyard M. Relative prognostic value of clinical heart failure and early echocardiographic parameters in acute myocardial infarction. Cardiology. 1991;79(1):64–72. doi: 10.1159/000174861. [DOI] [PubMed] [Google Scholar]
  3. Berning J., Steensgaard-Hansen F. Early estimation of risk by echocardiographic determination of wall motion index in an unselected population with acute myocardial infarction. Am J Cardiol. 1990 Mar 1;65(9):567–576. doi: 10.1016/0002-9149(90)91032-2. [DOI] [PubMed] [Google Scholar]
  4. Boissel J. P., Leizorovicz A., Picolet H., Peyrieux J. C. Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. Am J Cardiol. 1990 Aug 1;66(3):251–260. doi: 10.1016/0002-9149(90)90831-k. [DOI] [PubMed] [Google Scholar]
  5. Borg G. A. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377–381. [PubMed] [Google Scholar]
  6. Boström P. A., Balldin M., Lilja B., Johansson B. The effect of atenolol on the left ventricular performance in patients with angina pectoris measured with isotope technique. Acta Med Scand. 1988;223(3):239–245. doi: 10.1111/j.0954-6820.1988.tb15793.x. [DOI] [PubMed] [Google Scholar]
  7. Chadda K., Goldstein S., Byington R., Curb J. D. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation. 1986 Mar;73(3):503–510. doi: 10.1161/01.cir.73.3.503. [DOI] [PubMed] [Google Scholar]
  8. Currie P. J., Kelly M. J., McKenzie A., Harper R. W., Lim Y. L., Federman J., Anderson S. T., Pitt A. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. J Am Coll Cardiol. 1984 Jan;3(1):203–209. doi: 10.1016/s0735-1097(84)80449-0. [DOI] [PubMed] [Google Scholar]
  9. Dwyer E. M., Jr, Greenberg H. M., Steinberg G. Clinical characteristics and natural history of survivors of pulmonary congestion during acute myocardial infarction. The Multicenter Postinfarction Research Group. Am J Cardiol. 1989 Jun 15;63(20):1423–1428. doi: 10.1016/0002-9149(89)90001-5. [DOI] [PubMed] [Google Scholar]
  10. Engelmeier R. S., O'Connell J. B., Walsh R., Rad N., Scanlon P. J., Gunnar R. M. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation. 1985 Sep;72(3):536–546. doi: 10.1161/01.cir.72.3.536. [DOI] [PubMed] [Google Scholar]
  11. Gardin J. M., Henry W. L., Savage D. D., Ware J. H., Burn C., Borer J. S. Echocardiographic measurements in normal subjects: evaluation of an adult population without clinically apparent heart disease. J Clin Ultrasound. 1979 Dec;7(6):439–447. doi: 10.1002/jcu.1870070606. [DOI] [PubMed] [Google Scholar]
  12. Hjalmarson A., Elmfeldt D., Herlitz J., Holmberg S., Málek I., Nyberg G., Rydén L., Swedberg K., Vedin A., Waagstein F. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet. 1981 Oct 17;2(8251):823–827. doi: 10.1016/s0140-6736(81)91101-6. [DOI] [PubMed] [Google Scholar]
  13. Ikram H., Fitzpatrick D. Double-blind trial of chronic oral beta blockade in congestive cardiomyopathy. Lancet. 1981 Sep 5;2(8245):490–493. doi: 10.1016/s0140-6736(81)90881-3. [DOI] [PubMed] [Google Scholar]
  14. Jafri S. M., Khaja F., McFarland T., Capone R., Dahdah S., Haywood J., Edmiston W. A., Jr, Tilley B., Schultz L., Goldstein S. Efficacy of propranolol therapy after acute myocardial infarction related to coronary arterial anatomy and left ventricular function. Am J Cardiol. 1987 Nov 1;60(13):976–980. doi: 10.1016/0002-9149(87)90336-5. [DOI] [PubMed] [Google Scholar]
  15. Leier C. V., Patterson S. E., Huss P., Parrish D., Unverferth D. V. The hemodynamic and clinical responses to terazosin, a new alpha blocking agent, in congestive heart failure. Am J Med Sci. 1986 Sep;292(3):128–135. doi: 10.1097/00000441-198609000-00002. [DOI] [PubMed] [Google Scholar]
  16. Leung W. H., Lau C. P., Wong C. K., Cheng C. H., Tai Y. T., Lim S. P. Improvement in exercise performance and hemodynamics by labetalol in patients with idiopathic dilated cardiomyopathy. Am Heart J. 1990 Apr;119(4):884–890. doi: 10.1016/s0002-8703(05)80327-8. [DOI] [PubMed] [Google Scholar]
  17. Mulieri L. A., Hasenfuss G., Leavitt B., Allen P. D., Alpert N. R. Altered myocardial force-frequency relation in human heart failure. Circulation. 1992 May;85(5):1743–1750. doi: 10.1161/01.cir.85.5.1743. [DOI] [PubMed] [Google Scholar]
  18. Olsson G., Rehnqvist N. Effect of metoprolol in postinfarction patients with increased heart size. Eur Heart J. 1986 Jun;7(6):468–474. doi: 10.1093/oxfordjournals.eurheartj.a062093. [DOI] [PubMed] [Google Scholar]
  19. Olsson G., Rehnqvist N., Lundman T., Melcher A. Metoprolol treatment after acute myocardial infarction. Effects on ventricular arrhythmias and exercise tests during 6 months. Acta Med Scand. 1981;210(1-2):59–65. [PubMed] [Google Scholar]
  20. Persson H., Linder-Klingsell E., Eriksson S. V., Erhardt L. Heart failure after myocardial infarction: the importance of diastolic dysfunction. A prospective clinical and echocardiographic study. Eur Heart J. 1995 Apr;16(4):496–505. doi: 10.1093/oxfordjournals.eurheartj.a060942. [DOI] [PubMed] [Google Scholar]
  21. Pollock S. G., Lystash J., Tedesco C., Craddock G., Smucker M. L. Usefulness of bucindolol in congestive heart failure. Am J Cardiol. 1990 Sep 1;66(5):603–607. doi: 10.1016/0002-9149(90)90488-m. [DOI] [PubMed] [Google Scholar]
  22. Thierfelder L., Holubarsch C., Hasenfuss G., Heiss H. W., Just H. The effect of the partial beta-1-adrenoceptor agonist xamoterol on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol. 1991 Apr;17(4):593–599. doi: 10.1097/00005344-199104000-00011. [DOI] [PubMed] [Google Scholar]
  23. Vigholt-Sørensen E., Faergeman O., Snow H. M. Effects of xamoterol, a beta 1 adrenoceptor partial agonist, in patients with ischaemic dysfunction of the left ventricle. Br Heart J. 1989 Nov;62(5):335–341. doi: 10.1136/hrt.62.5.335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Waagstein F., Bristow M. R., Swedberg K., Camerini F., Fowler M. B., Silver M. A., Gilbert E. M., Johnson M. R., Goss F. G., Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993 Dec 11;342(8885):1441–1446. doi: 10.1016/0140-6736(93)92930-r. [DOI] [PubMed] [Google Scholar]
  25. Waller D. G., Webster J., Sykes C. A., Bhalla K. K., Wray R. Clinical efficacy of xamoterol, a beta 1-adrenoceptor partial agonist, in mild to moderate heart failure. U.K. Xamoterol Study Group. Eur Heart J. 1989 Nov;10(11):1003–1010. doi: 10.1093/oxfordjournals.eurheartj.a059412. [DOI] [PubMed] [Google Scholar]
  26. Wolk M. J., Scheidt S., Killip T. Heart failure complicating acute myocardial infarction. Circulation. 1972 May;45(5):1125–1138. doi: 10.1161/01.cir.45.5.1125. [DOI] [PubMed] [Google Scholar]
  27. Yusuf S., Peto R., Lewis J., Collins R., Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335–371. doi: 10.1016/s0033-0620(85)80003-7. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES